Ranibizumab
| Evidence Level: L1 | Predicted Indications: 10 |
Table of Contents
- Ranibizumab
- Ranibizumab: From Neovascular AMD/Diabetic Macular Edema to Severe Nonproliferative Diabetic Retinopathy
Ranibizumab: From Neovascular AMD/Diabetic Macular Edema to Severe Nonproliferative Diabetic Retinopathy
One-Sentence Summary
Ranibizumab is an anti-VEGF-A antibody fragment whose approved indications elsewhere include neovascular (wet) age-related macular degeneration and diabetic macular edema (DME). The TxGNN model predicts it may be effective for severe nonproliferative diabetic retinopathy (NPDR), with 6 clinical trials (including two completed Phase 3 RCTs) and 19 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this evidence pack’s EU authorization data (product currently not marketed). The pack’s own rationale notes ranibizumab already holds approved DME/DR-adjacent indications in other markets. |
| Predicted New Indication | Severe nonproliferative diabetic retinopathy |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L1 |
| EU Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on the information provided, ranibizumab is an anti-VEGF-A Fab fragment; VEGF-A is a well-established driver of the abnormal angiogenesis and vascular leakage seen in diabetic retinopathy.
Per the repurposing rationale accompanying this prediction: “VEGF-A drives the angiogenesis and vascular leakage underlying diabetic retinopathy. Ranibizumab, as an anti-VEGF-A Fab fragment, has a mechanism that directly aligns with this pathology. In most markets, this indication is already label-adjacent — overlapping substantially with ranibizumab’s existing approved indications for diabetic macular edema (DME) and diabetic retinopathy (DR).”
This mechanistic overlap is reinforced by an extensive clinical trial history: DRCR.net Protocol I/S and the RIDE/RISE program have repeatedly demonstrated that intravitreal ranibizumab reduces DR severity scores and delays progression to vision-threatening complications, providing strong biological plausibility for extending use specifically to the severe NPDR stage.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00444600 | Phase 3 | Completed | 691 | DRCR.net Protocol I — compared laser alone, laser + triamcinolone, laser + ranibizumab, and ranibizumab alone for diabetic macular edema |
| NCT02634333 | Phase 3 | Completed | 399 | Intravitreal anti-VEGF for prevention of vision-threatening complications in high-risk DR eyes |
| NCT02834663 | Phase 4 | Completed | 25 | Intravitreal ranibizumab in NPDR with DME — effects on microaneurysm turnover and non-perfused retinal area |
| NCT03452657 | Phase 3 | Unknown | 118 | Efficacy/safety of intravitreous ranibizumab vs sham injections for prevention of high-risk DR progression |
| NCT04503551 | Phase 3 | Active, not recruiting | 174 | Port Delivery System with ranibizumab vs comparator in DR without center-involved DME |
| NCT05222633 | N/A | Unknown | 1000 | Real-world observational study of anti-VEGF therapy across AMD/PDR/ME/CNV populations (indirect relevance) |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 40048178 | 2025 | RCT | JAMA Ophthalmology | Pavilion trial: Port Delivery System with ranibizumab vs monitoring in NPDR without macular edema |
| 40347224 | 2025 | Systematic Review | Health Technology Assessment | Anti-VEGF vs laser photocoagulation for DR — systematic review and economic analysis |
| 39673354 | 2024 | Systematic Review | Health Technology Assessment | Anti-VEGF vs laser photocoagulation for DR — systematic review and meta-analysis |
| 36774994 | 2023 | Cohort (post-hoc meta-analysis) | Ophthalmology Retina | Baseline DR severity and time to DME resolution with ranibizumab in Phase 3 trials |
| 35417296 | 2022 | Cohort (post-hoc) | Ophthalmic Surgery, Lasers & Imaging Retina | DR course in untreated fellow eyes in RIDE/RISE — natural history comparator |
| 33966556 | 2021 | Review | Expert Opinion on Biological Therapy | Ranibizumab for the treatment of diabetic retinopathy — mechanism and evidence overview |
| 32606578 | 2020 | Cohort (RIDE/RISE post-hoc) | Clinical Ophthalmology | Predictors of early DR regression with ranibizumab in RIDE and RISE trials |
| 31669065 | 2019 | Review | Journal of Diabetes and its Complications | Advances in the treatment of diabetic retinopathy, VEGF-A pathophysiology |
| 30234859 | 2018 | RCT-derived (DRCR.net Protocol I, 5-yr report) | Retina | Changes in DR severity when treating DME with ranibizumab over 5 years |
| 28448655 | 2017 | Secondary analysis of RCT | JAMA Ophthalmology | 2-year DR change comparing aflibercept, bevacizumab, and ranibizumab |
EU Market Information
No EU marketing authorizations are recorded for ranibizumab in this evidence pack (total_licenses = 0, product status: Not Marketed). No product-level authorization details are available to tabulate.
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The evidence level is L1 — two completed Phase 3 RCTs (DRCR.net Protocol I, NCT02634333) plus a completed Phase 4 study directly support ranibizumab’s effect on diabetic retinopathy severity, and two 2024–2025 systematic reviews independently confirm anti-VEGF efficacy in DR. However, this specific evidence pack lacks confirmed EU marketing status and safety/regulatory documentation, so guardrails are warranted before advancing.
To proceed, the following is needed:
- TFDA/EU label warnings and contraindications (currently a Blocking data gap — required before any S1 safety screening)
- Verified mechanism of action documentation from DrugBank (currently a High-severity data gap affecting mechanistic-link analysis)
- Confirmation of actual EU marketing authorization status, since this evidence pack shows zero licenses despite ranibizumab’s well-documented clinical trial history
- A distinction between “severe NPDR” as a standalone indication versus the already-overlapping DME/PDR indications, to clarify true label-adjacency
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.